GlassScriptPhysician profile
Maxx Ramirez
NPI 1083123509
$7,148.45
in general payments reported to CMS, 2019-2025
40 companies · $2,740 in 2025
The $2,740 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $1,700 · 2023: $852 · 2024: $1,541 · 2025: $2,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996 · Honoraria: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,995.74 |
| Honoraria | $1,137.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,353.98 | 2022-2025 | Intracept, Intracept Rf Probe, Wavewriter Alpha Prime 16 |
| Protega Pharmaceutials INC | $1,288.10 | 2024-2025 | Roxybond |
| Relievant Medsystems, INC. | $685.50 | 2022-2023 | Intracept |
| Collegium Pharmaceutical, INC. | $619.92 | 2022-2025 | Xtampza |
| Abbvie INC. | $515.44 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $482.36 | 2021-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $246.77 | 2021-2023 | Ajovy |
| Globus Medical, INC. | $210.10 | 2025 | Senza |
| Medtronic, INC. | $198.99 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Pfizer INC. | $187.33 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $127.40 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $110.01 | 2021-2024 | Ztlido |
| Pacira Therapeutics, INC. | $86.12 | 2021 | |
| Saluda Medical Americas, INC. | $84.34 | 2023-2024 | Evoke Scs, Evoke |
| Abbott Laboratories | $83.47 | 2021-2024 | Proclaim |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $69.58 | 2021 | |
| Nevro Corp. | $68.96 | 2024 | Senza |
| Fidia Pharma USA INC. | $61.51 | 2022-2024 | Hyalgan, Hymovis, Triluron |
| Vertos Medical, INC. | $54.96 | 2022-2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $47.62 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $45.14 | 2023-2024 | Zilretta, Iovera, Exparel |
| Spinal Simplicity, LLC | $44.10 | 2025 | Ha Minuteman G3-R |
| Vertex Pharmaceuticals Incorporated | $43.02 | 2025 | |
| Atland Pharmaceuticals, LLC | $42.34 | 2024-2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Lilly USA, LLC | $42.29 | 2021-2022 | |
| Si-Bone, INC. | $42.05 | 2024-2025 | |
| Curonix LLC | $36.57 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Amgen INC. | $29.97 | 2024 | Krystexxa |
| Allergan, INC. | $26.43 | 2022 | |
| Spr Therapeutics, INC | $26.21 | 2024 | Sprint Pns System |
| Stryker Corporation | $24.36 | 2025 | Optablate |
| Nalu Medical, INC. | $23.83 | 2025 | Nalu Neurostimulation System |
| Heron Therapeutics, INC. | $20.70 | 2021 | |
| Averitas Pharma INC. | $20.37 | 2024 | Qutenza |
| Valinor Pharma, LLC | $19.92 | 2025 | Movantik |
| Idorsia Pharmaceuticals US INC | $18.99 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $18.84 | 2022 | |
| Bioventus LLC | $16.45 | 2022 | |
| Smith+Nephew, INC. | $12.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxx Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.